Regulators Discuss QbD Challenges While Industry Attests That Business Benefits of QbD Still Unknown
This article was originally published in The Gold Sheet
Regulators in the European Union and U.S. say that the concepts of design space, control strategy, and critical quality attributes are confusing to pharmaceutical manufacturers and are working to address this to ease quality by design implementation. In the meantime industry representatives say that it is still too early to make a definitive business case for QbD but that early signs are promising.
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
EU Pharmaceutical Industry Starting to Incorporate More QbD-Like Elements in Applications; EU Inspectors Looking to Align Inspections with New Paradigm
Quality by Design is advancing in Europe as manufacturers incorporate more QbD elements into their applications and EU regulators begin adjusting their inspections to address QbD-related issues. Decentralized review for most applications slows advance of QbD. Discussion of mock submissions spurs interest. EMEA/EFPIA meeting focuses on QbD issues companies raised privately. PDA launches PCMO initiative for sharing best practices. The increasing pain of over-inspections.
Pfizer's third US FDA warning letter since 2018 goes to injectables site in Vizag, India; tells the company to up its game in sterility testing and in the microbiology lab.